- Home
- CVKD vs MIRA Comparison
CVKD vs MIRA Comparison
Compare CVKD & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MIRA
- Stock Information
- Founded
- CVKD 2022
- MIRA 2020
- Country
- CVKD United States
- MIRA United States
- Employees
- CVKD N/A
- MIRA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- MIRA Health Care
- Exchange
- CVKD Nasdaq
- MIRA Nasdaq
- Market Cap
- CVKD 29.5M
- MIRA 19.5M
- IPO Year
- CVKD 2023
- MIRA 2023
- Fundamental
- Price
- CVKD $12.99
- MIRA $1.11
- Analyst Decision
- CVKD Strong Buy
- MIRA Strong Buy
- Analyst Count
- CVKD 1
- MIRA 2
- Target Price
- CVKD $32.00
- MIRA $14.00
- AVG Volume (30 Days)
- CVKD 33.5K
- MIRA 2.1M
- Earning Date
- CVKD 08-06-2025
- MIRA 08-12-2025
- Dividend Yield
- CVKD N/A
- MIRA N/A
- EPS Growth
- CVKD N/A
- MIRA N/A
- EPS
- CVKD N/A
- MIRA N/A
- Revenue
- CVKD N/A
- MIRA N/A
- Revenue This Year
- CVKD N/A
- MIRA N/A
- Revenue Next Year
- CVKD N/A
- MIRA N/A
- P/E Ratio
- CVKD N/A
- MIRA N/A
- Revenue Growth
- CVKD N/A
- MIRA N/A
- 52 Week Low
- CVKD $5.70
- MIRA $0.51
- 52 Week High
- CVKD $22.90
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- CVKD 49.88
- MIRA 37.61
- Support Level
- CVKD $11.00
- MIRA $1.07
- Resistance Level
- CVKD $13.56
- MIRA $1.39
- Average True Range (ATR)
- CVKD 1.11
- MIRA 0.09
- MACD
- CVKD 0.23
- MIRA -0.02
- Stochastic Oscillator
- CVKD 80.67
- MIRA 6.25
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.